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Abstract: The nucleotide-binding oligomerization domain (NOD) protein, NOD2, belonging to 
the intracellular NOD-like receptor family, detects conserved motifs in bacterial peptidoglycan 
and promotes their clearance through activation of a proinflammatory transcriptional program 
and other innate immune pathways, including autophagy and endoplasmic reticulum stress. 
An inactive form due to mutations or a constitutive high expression of NOD2 is associated 
with several inflammatory diseases, suggesting that balanced NOD2 signaling is critical for 
the maintenance of immune homeostasis. In this review, we discuss recent developments about 
the pathway and mechanisms of regulation of NOD2 and illustrate the principal functions of 
the gene, with particular emphasis on its central role in maintaining the equilibrium between 
intestinal microbiota and host immune responses to control inflammation. Furthermore, we sur-
vey recent studies illustrating the role of NOD2 in several inflammatory diseases, in particular, 
inflammatory bowel disease, of which it is the main susceptibility gene.
Keywords: innate immunity, intestinal homeostasis, ER stress, autophagy, inflammatory bowel 
disease, extraintestinal disease
Introduction
The human body is constantly in contact with a myriad of microorganisms, either 
pathogens or commensals. Innate immune system, which provides a first line of defense 
against many common microbes, is essential for an appropriate tissue homoeostasis 
as well as for common bacterial infections, and its dysfunction leads to infectious, 
inflammatory and autoimmune diseases.
Innate immune response relies on recognition of evolutionarily conserved structures 
on the microorganisms, termed pathogen-associated molecular patterns (PAMPs), 
through a limited number of germ line-encoded pattern recognition receptors (PRRs) 
present on the host cell surface or in the intracellular compartments.1 Among the lat-
ter, nucleotide-binding and oligomerization domain containing protein 2 (NOD2) is 
a cytosolic receptor belonging to the nucleotide-binding oligomerization (NOD)-like 
receptor (NLR) family.2 NOD2 is able to detect intracellular muramyl dipeptide (MDP), 
a component of the bacterial wall that is ubiquitously present in bacterial peptidogly-
can.3 Upon activation by ligand, NOD2 mediates innate immune response triggering 
proinflammatory responses. NOD2 mutation or altered expression has been found 
in patients with chronic inflammatory disorders such as Crohn’s disease (CD), Blau 
syndrome (BS) and early-onset sarcoidosis (EOS).4–9 In this review, we summarize the 
current knowledge about NOD2 functions and regulation, as well as its involvement 
in chronic inflammatory diseases.
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The NLR family
The 23 NLR family members, intracellular sensors of 
PAMPs, share a common organization consisting of a 
C-terminal leucine-rich repeat (LRR) domain with regulatory 
and ligand recognition functions, a central nucleotide-binding 
and oligomerization domain (NBD) and an N-terminal 
effector-binding domain. The type of effector domain results 
in the division of NLR proteins into five subfamilies: acidic 
transactivation domain (NLRA); baculovirus inhibitor repeat, 
BIR (NLRB); caspase recruitment domain, CARD (NLRC); 
pyrin domain (NLRP) and NLRX1 that localizes to the 
mitochondria and has no homology to any known N-terminal 
domain (Figure 1).10,11 NOD2 belongs to the NLRC subfamily 
of NLRs and, after NOD1, has been the second member of 
the family to be identified.12 NOD2 receptor, encoded by the 
NOD2/CARD15 gene, mapping on chromosome 16q12.1 in 
humans, consists of 1040 amino acids and has a molecular 
weight of 110 kDa.12 It is expressed in monocytes, macro-
phages, dendritic cells, hepatocytes, preadipocytes, epithelial 
cells of oral cavity, lung and intestine, with higher expression 
in ileal Paneth cells and in intestinal stem cells.13,14 NOD2, 
like NOD1, is a cytoplasmic protein, although it is recruited 
in the plasmatic membrane where it detects bacterial invasion 
at the point of entry.15
NOD2 signaling
The innate immune system is critical for clearing infection 
and averting excessive tissue damage. NOD2, an intracellular 
receptor of microbial components derived from bacterial 
peptidoglycan, contributes to the maintenance of mucosal 
homeostasis and the induction of mucosal inflammation. 
Structurally, NOD2 protein is composed of two tandem 
N-terminal CARDs that function as effector domain and 
mediate specific homophilic interaction with downstream 
CARD-containing molecules.16 On activation by MDP, a cell 
wall component of both Gram-positive and Gram-negative 
bacteria, through LRR domain, NOD2 undergoes self-
oligomerization and recruitment of the downstream adaptor 
molecule, the kinase receptor interacting protein 2 (RIP2 
also known as RICK, CARDIAK, CCK and Ripk2), via 
homophilic CARD–CARD interaction.17–19 Active RIP2 leads 
to ubiquitination of nuclear factor-kappa B (NF-κB) essen-
tial modulator, resulting in activation of IκB kinase (IKK) 
complex that phosphorylates NF-κB inhibitor-α (IKBα), the 
inhibitor of transcription factor NF-κB, which translocates to 
the nucleus and starts transcription of proinflammatory genes, 
including cytokines, growth factors and factors responsible 
for stimulation of immune cells.20,21 RIP2 targets transform-
ing growth factor-β-activated kinase 1, which, through IKK 
Figure 1 Structure of the NLR subfamilies.
Abbreviations: AD, atopic dermatitis; BIR, baculovirus inhibitor repeat; CARD, caspase recruitment domain; CIITA, class II major histocompatibility complex transactivator; 
FIIND, function to find domain; LRR, leucine-rich repeat; NAD, NBD-associated domain; NBD, nucleotide-binding domain; NLR, NOD-like receptor; NLRA, acidic 
transactivation domain; NLRB, baculovirus inhibitor repeat; NLRC, caspase recruitment domain; NLRP, NLR family pyrin domain; NOD, nucleotide-binding oligomerization 
domain; PYD, pyrin domain; X, unknown effector domain.
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complex, activates MAP kinases and transcription factor Acti-
vator Protein 1 involved in cell proliferation, differentiation 
and apoptosis.18,22 NOD2 is also known to bind and activate 
caspase-1, through its CARD domain, and starts interleukin 
(IL)-1β processing.23 Moreover, MDP challenge promotes the 
formation of NOD2–NLR family pyrin domain containing 1 
complex that induces caspase-1–dependent IL-1β secretion in 
response to Bacillus anthracis or Yersinia pseudotuberculosis 
infection.23,24 Recently, NOD2 has been suggested to have a 
role in the autophagic process due to its interaction with the 
autophagy protein Autophagy Related 16 Like 1 (ATG16L1), 
which has been described below in-depth (Figure 2).25
NOD2 regulation
The complexity of NOD2 signaling is underlined by the evi-
dence that many cellular proteins interact with NOD2 directly 
and regulate positively or negatively its functional  activity.26 
Among these, Erbin, Centaurin B1,  Angio-Associated 
Migratory Cell Protein, Carbamoyl-Phosphate Synthe-
tase 2,  Mitogen-Activated Protein Kinase Binding Protein 1 
(JNKBP1) and heat shock protein (HSP) 90 have been shown 
to interact with NOD2 and regulate downstream signaling 
events.26–30 Recently, Suppressor of Cytokine Signaling-3 was 
found to recruit the ubiquitin machinery to NOD2, facilitating 
its proteasomal degradation.30 Interferon regulatory factor 4 
(IRF4) is another negative regulator of NOD2-dependent 
NF-κB signaling through inhibition of RIP2 polyubiquitina-
tion in human dendritic cells.31 On the contrary, HSP70 and 
FERM and PDZ domain-containing protein 2 act as positive 
regulators of NOD2 signaling: the first one, after binding with 
NOD2, leads to increase in NF-κB activity and the second 
one favors NOD2 localization at the plasma membrane.29,32
Furthermore, important posttranslational modifications 
are required to control NOD2 signaling.33 The E3 ubiquitin 
ligases Pellino 3 and X-linked inhibitor of apoptosis protein, 
by ubiquitinylating RIP2, are important mediators in the 
Figure 2 Signaling pathways triggered by NOD2.
Abbreviations: AP-1, activator protein-1; ATF6, activating transcription factor 6; ATG, autophagy-related genes; ATG16L1, autophagy related 16 like 1; ER, endoplasmic 
reticulum; ERK, extracellular signal-regulated kinase; IFNs, interferons; IKB, NF-κB inhibitor; IKK, IκB kinase; IRF3, interferon response factor 3; JNK, c-Jun N-terminal 
kinase; MAVS, mitochondrial antiviral signaling; MDP, muramyl dipeptide; NEMO, NF-κB essential modulator; NOD, nucleotide-binding oligomerization domain; PERK, 
protein kinase RNA-like endoplasmic reticulum kinase; RIP2, receptor-interacting protein kinase 2; TAB, TGF-β activated kinase; TAK1, targets transforming growth factor-
β-activated kinase 1; UPR, unfolded protein response.
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NOD2 pathway and regulators of intestinal inflammation.34,35 
Interestingly, loss of Pellino 3 decreases RIP2 ubiquitina-
tion and activation of NF-κB and mitogen-activated protein 
kinases (MAPKs), while genetic X-linked inhibitor of 
apoptosis protein loss causes a blunted NOD2 response.34–36 
Tripartite Motif Containing 27 negatively regulates NOD2 
by ubiquitination, while the E3-ubiquitin ligase ZNRF4, 
degrading RIP2, is a negative regulator of NOD2-induced 
NF-κB activity as well.37,38 Differently, the ovarian tumor 
family deubiquitinase OTULIN was shown to dampen NOD2 
signaling by increasing NF-κB transcription.39
A recent study shows that leucine-rich repeat kinase 2, 
whose polymorphisms have been associated with CD, leprosy 
and familiar Parkinson’s disease, is a new RIP2-positive 
regulator by enhancing RIP2 phosphorylation upon NOD2 
activation.40
NOD2 signaling is known to be regulated by cytoskeleton 
elements also: the intermediate filament protein vimentin has 
been recently shown to interact with NOD2, in response to 
MDP, and affect NF-κB induction.41
Large evidence supports the role of several microRNAs, 
including mir-320, miR-192, miR-122, miR-512, miR-671 
and miR-495, as new important NOD2 regulators.42,43
NOD2 genetics
Hereditary polymorphisms in the gene encoding NOD2 have 
been associated with an increasing number of chronic inflam-
matory diseases, such as CD, BS and EOS.6–8
In particular, the three main NOD2 polymorphisms, 
R702W (Arg702Trp), G908R (Gly908Arg) and L1007fsinsC, 
are highly associated with susceptibility to CD.6,7,44 R702W 
and G908R mutations are single amino acid changes within 
the LRR domain, whereas the L1007fsinsC mutation is 
caused by a deletion producing a reading frameshift that 
leads to the loss of 33 amino acids.6,7 CD-associated muta-
tions result in NOD2 loss of functions, with a reduced 
responsiveness to MDP, enabling invasion of bacteria and 
abnormal mucosal immune response, which culminates in 
chronic intestinal inflammation.5–7
The variants in the NBD and in between the NBD and 
LRR are associated to BS, EOS and NOD2-associated auto-
inflammatory disease, respectively.8,9,45,46
At least 17 different mutations have been identified in 
the NBD domain of NOD2,45 of which the following four 
missense mutations are the most abundant: Arg334Glu 
(R334Q), Arg334Trp (R334W) and Leu469Phe (L469F), 
which together account for 80% of the cases, and Glu383Lys 
(E383K) (5% of cases).47 Other NOD2 mutations, like the 
Arg314Glu (R314Q) polymorphism that codes for a trun-
cated form of the protein, have been described most rarely.8 
These mutations are supposed to be gain of function, causing 
excessive NF-κB and MAPK activation.9
NOD2 functions
NOD2 and intestinal microbiota
Humans are colonized by a collection of microbes, the largest 
numbers of which reside in the distal gut. The constant expo-
sure of the intestinal tissue to gut microorganisms maintains 
the mucosa in a state of physiological inflammation, which 
balances tolerogenic and proinflammatory type responses to 
maintain homeostasis.48 Several studies highlight the essential 
role that NOD2 plays in maintaining the equilibrium between 
microbiome and host immune responses.49–51 An imbalance 
in this relationship results in dysbiosis, whereby pathogenic 
bacteria prevail on commensals, causing damage in the intes-
tinal epithelial barrier as well as allowing bacterial invasion 
and inflammation.52,53 A negative feedback loop between 
NOD2 and commensal bacteria function has been described, 
whereby commensal bacteria promote NOD2 expression, 
which in turn prevents their over-expansion.52 Since NOD2 is 
an intracellular microbial sensor for gram-positive and gram-
negative bacteria, it has been proposed that its deficiency or 
mutations can contribute to the modification of microbial 
composition and disease development in animal models.18,51,52
NOD2-deficient mice show a reduced number of intestinal 
intraepithelial lymphocytes impairing the epithelium integ-
rity and leading to altered immune response to the resident 
microbiota.54 Moreover, NOD2- and RIP2-deficient mice 
show increased sensitivity to dextran sulfate sodium-induced 
colitis and colonic adenocarcinoma due to dysbiosis, which is 
transmitted to wild-type (WT) mice through the microbiota.55 
NOD2 is also a critical regulator of microbiota in the small 
intestine.13 Indeed, NOD2 is highly expressed in Paneth cells, 
specialized cells located at the base of the intestinal crypts of 
Lieberkuhn, which are responsible for the ileal microbiota by 
secreting antimicrobial compounds, in response to bacterial 
products, including MDP, the agonist of NOD2.13,18,56
There is evidence that NOD2 mutations increase the sus-
ceptibility to abnormal ileal inflammation. NOD2-deficient 
mice display Paneth and goblet cell dysfunction that promotes 
larger loads of bacteria in the ileum, including Bacteroides 
vulgatus, and excessive interferon-γ (IFNγ) production.53,57
However, several studies do not support the evidence of a 
relationship between NOD2 mutations and altered microbiota 
composition, suggesting the contribution of other factors 
independent of the genotype, such as maternal microbiota 
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transmission or environmental causes, but results are still 
controversial.58–60 NOD2 participates in the recognition 
of a subset of pathogenic microorganisms that are able to 
invade and multiply intracellularly, such as  Campylobacter, 
Citrobacter, Escherichia, Helicobacter, Listeria, Mycobac-
teria, Pseudomonas, Staphylococcus, Yersinia and other 
 species.51,61,62 In a murine skin Staphylococcus aureus infec-
tion model, Nod2−/− mice show skin lesions and increased 
bacterial numbers in the skin, compared to WT mice.63 
Moreover, NOD2-deficient mice show a higher fecal bacterial 
load after Citrobacter rodentium infection, besides increased 
susceptibility to enteric Salmonella spp. and an impaired 
activation of Th17 cells after C. rodentium or Salmonella spp. 
exposure.64–66 Interestingly, NOD2L1007fsinsC mutants show 
a lower reactive oxygen species production and a reduced 
protection against bacterial invasion.67
NOD2 upregulation following vitamin D treatment 
results in increased killing of pneumococci in patients with 
frequent respiratory tract infections.68 Bacterial lipoprotein-
tolerogenic macrophages show improved NOD1/NOD2-
dependent bactericidal activity to Sta. aureus and Salmonella 
typhimurium.69
NOD2 cooperates with other proteins for defense against 
pathogens, such as the autophagic protein ATG16L1 and 
the oxidase dual oxidase 2 that represents a major source 
of NOD2-dependent bactericidal reactive oxygen species 
generation.70
NOD2 in innate and adaptive immunity
NOD2 drives the innate inflammatory response to bacteria 
and viruses through the activation of NF-κB, MAPK and 
caspase-1 pathways, which results in increased expression 
of proinflammatory factors, including IL-1β, tumor necro-
sis factor-alpha (TNFα), IL-6, IL-12p40, CC-chemokine 
ligand 2, the neutrophil chemoattractants CXC-chemokine 
ligand 8 (also known as IL-8), CXC-chemokine ligand 2 
as well as various antimicrobial agents, as defensins, and 
in recruitment and priming of neutrophils, inflammatory 
monocytes and dendritic cells.64,71–73
NOD2 also activates other signaling pathways. Upon 
binding the bacterial ligand, NOD2 induces recruitment of 
RIP2, which binds TNF receptor-associated factor (TRAF) 
3 that activates the TANK binding kinase 1 and IKKε, 
which phosphorylates and activates regulatory interferon 
response factor 3 (IRF3). Activated IRF3 passes into the 
nucleus, where it binds with the molecules of IFN-stimulated 
response elements inducing the IFN gene expression of 
type I.74,75
Moreover, NOD2 triggers Notch1 signaling response. 
Crosstalk between NOD2 and its novel downstream effector 
Notch1-PI3K in the macrophages contributes to macrophage 
survival, reducing TNFα/IFNγ-induced apoptosis, and modu-
lates the expression of IL-10 and a battery of genes associated 
with anti-inflammatory functions.76
In addition to its main role in innate immunity, NOD2 is 
capable of activating the adaptive immune system; indeed, it 
is a key driver of T helper (Th) 2-type immunity resulting in 
IL-4 and IL-5 production.77 Full Th2 induction upon Nod2 
activation is dependent on both thymic stromal lymphopoietin 
production by the stromal cells and the upregulation of the co-
stimulatory molecule, OX40 ligand, on the dendritic cells.77 
Several studies have shown that co-stimulation with NOD2 
and toll-like receptor (TLR) agonists induces a synergistic 
production of Th1-associated cytokines in different types of 
cells, although the mechanism is still unclear.78,79
Finally, MDP-induced NOD2 activation has been shown 
to promote the development of  Th17 cells and the conse-
quent production of IL-17A, IL-17F, IL-21 and IL-22.80,81
NOD2 and antiviral response
The innate immune system detects viral infections through 
the recognition of virus-associated PAMPs, such as genomic 
DNA, RNA or dsRNA produced in infected cells, which are 
recognized by the PRRs expressed in innate immune cells.82 
After recognition of the viral components, PRRs activate an 
antiviral response that results in the production of type I IFNs, 
proinflammatory cytokines, eicosanoids and chemokines and 
subsequent induction of adaptive immune response.82 Cur-
rent literature evidences that NOD2 is also able to control 
virus infections.83,84 Indeed, the antiviral SB 9200, a novel 
first-in-class oral modulator of innate immunity with a broad-
spectrum activity in vitro and in vivo against RNA viruses 
including hepatitis C virus, norovirus, respiratory syncytial 
virus and hepatitis B virus, is also believed to act via NOD2 
pathway.85 Furthermore, infection with human cytomegalo-
virus results in significant induction of NOD2 expression, 
activating downstream NF-κB and IFN pathways.84 Besides, 
following recognition of a viral ssRNA genome, NOD2 
uses the adaptor mitochondrial antiviral signaling protein 
to activate IRF3; interestingly, NOD2-deficient mice fail to 
produce IFN efficiently. Similar roles for NOD2 are observed 
in response to influenza A and parainfluenza viruses.75
NOD2-induced triggering of NF-κB and IRF3 in response 
to viral infection is also interesting since it has been shown 
that a coordinated activation of NF-κB and IRF3 pathways 
synergistically promotes optimal IFN expression, including 
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IFN-β, and hence the antiviral resistance.86 Moreover, a regu-
latory role of NOD2 in enhancing the function of RNase-L 
through the binding with 2′-5′-oligoadenylate synthetase 
type 2, a dsRNA binding protein, has been described as an 
additional strategy to induce an innate immune response to 
control bacteria and viruses.87
NOD2 and autophagy
Autophagy represents a cellular stress response that plays key 
roles in physiological processes, such as innate and adaptive 
immunity, adaptation to starvation, degradation of misfolded 
or aggregated proteins or damaged organelles and elimina-
tion of intracellular pathogens, in order to promote cellular 
survival. The role of NOD1 and NOD2 in autophagy is a 
recent discovery and still under debate.
Travassos et al suggested that, by a mechanism independent 
of the adaptor RIP2 and transcription factor NF-κB, NOD1 and 
NOD2 recruited the autophagy protein ATG16L1, an essential 
component of the autophagic machinery, to the plasma mem-
brane at the bacterial entry site.25 Moreover, in cells homo-
zygous for the CD-associated NOD2 frameshift mutation, 
mutant NOD2 failed to recruit ATG16L1 to the membrane 
and wrapping of invading bacteria by autophagosomes was 
impaired.25 Furthermore, knockdown of ATG16L1 resulted in 
specific upregulation of NOD2 response, establishing a role of 
ATG16L1 as a negative regulator of the NOD2/RIP2 pathway.88 
NOD2-mediated autophagy is crucial to hold intramucosal 
bacterial burden and limit intestinal inflammation.89–91
Interestingly, ATG16L1 and NOD2 single nucleotide 
polymorphisms are both implicated in increased susceptibil-
ity to CD.91–94
More recently, other authors have provided evidence of 
an alternative mechanism of NOD2-dependent autophagy 
activation which requires RIP2. Cooney et al have shown that 
NOD2 triggering by MDP induces autophagy in dendritic 
cells and this effect requires RIP2.95 Anand et al demonstrated 
that macrophages deficient in the TLR2 and NOD/RIP2 
pathway display defective autophagy induction in response 
to Listeria monocytogenes.96 Homer et al have shown a dual 
role for RIP2 tyrosine kinase activity in NOD2-dependent 
autophagy: RIP2 both sends a positive autophagy signal 
through activation of p38 MAPK and relieves repression of 
autophagy mediated by the phosphatase PP2A.97
NOD2 and endoplasmic reticulum (ER) 
stress
The ER stress, activated by accumulation of unfolded or 
misfolded proteins and microbial infections, triggers a host 
response known as the unfolded protein response (UPR), 
which involves the activation of three transmembrane recep-
tors: activating transcription factor 6, protein kinase RNA-
like ER kinase and inositol-requiring enzyme 1α (IRE1α). 
Once activated, IRE1α recruits TRAF2 to the ER membrane 
to initiate inflammatory responses via c-Jun N-terminal 
kinase (JNK) pathway and NF-κB.98 NOD2 was found to 
transduce ER stress signals to elicit inflammation.99,100 Indeed, 
TRAF2 has been shown to interact with NOD1 and NOD2 
to orchestrate this inflammatory branch of UPR, which also 
requires the adaptor protein RIP2.98 However, the mechanism 
by which ER stress, and more specifically IRE1α, activates 
NOD1/NOD2 signaling is still unclear. Recent work provides 
evidence that the ER stress inducers thapsigargin and dithio-
threitol trigger production of the proinflammatory cytokine 
IL-6 in a NOD1/2-dependent fashion.100,101 In vivo experi-
ments confirmed the in vitro observations by showing that 
systemic proinflammatory responses induced by thapsigargin 
administration were blunted in NOD1–/–NOD2–/– mice.100
Several UPR-related genes have been identified as inflam-
matory bowel disease (IBD) risk loci.102,103 In particular, new 
evidence has linked the UPR and autophagy in Paneth cells to 
the development of CD-like transmural ileitis.104 The genetic 
convergence of genetic polymorphisms on innate immune 
pathways, such as NOD2, autophagy and ER stress, may 
open novel therapeutic options for the treatment of intestinal 
inflammation.105,106 The involvement of ER stress and NOD2 
in chronic inflammatory diseases, including IBD and type 2 
diabetes, has important implications for understanding the 
pathogenesis and for the management of these diseases.107,108
NOD2 and IBD
IBD is a group of chronic multifactorial disorders that 
includes CD, characterized by transmural inflammation 
that can affect any region of the gastrointestinal tract and 
ulcerative colitis that results in inflammation and ulcers of 
the colon and rectum. The etiology of IBD has yet to be fully 
elucidated; however, it is postulated that it is the result of an 
unbalanced crosstalk between gut luminal content and the 
mucosal immune system in genetically susceptible hosts.109
Recent genome-wide association studies have revealed 
163 susceptibility loci for IBD.110 NOD2 was the first gene 
identified as a risk factor for ileal CD.6,7
Three NOD2 polymorphisms in the LRR region are 
directly associated with CD, of which the most known is the 
frameshift mutation (L1007fs), whereas the other two are 
missense mutations (R702W and G908R).6,7 It is postulated 
that the LRR domain of CD-associated variants is likely 
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to be impaired, possibly to various degrees, in recognizing 
microbial components and/or in physiologically inhibiting 
NOD2 dimerization, thus resulting in the inappropriate 
activation of NF-κB in monocytes, bacterial clearance and 
impairment of intestinal permeability.6,111,112 Thus, individuals 
who are heterozygous for NOD2 variants have a 2–4-fold 
increased risk of developing CD, whereas homozygous vari-
ants have an additional risk of 20–40-fold.6,7,113 However, 
many NOD2 variant carriers do not develop the disease, sug-
gesting that other factors are involved in disease onset.111,112 
Similarly, NOD2-knockout mice lack symptoms associated 
with spontaneous intestinal inflammation.114 Nevertheless, 
NOD2-deficient mice demonstrate defects in mediating 
antibacterial responses, such as increased systemic Listeria 
colonization, suggesting decreased antimicrobial peptides 
in their intestine.18 Moreover, NOD2-deficient mice show 
altered gut permeability.49 This evidence is also supported 
by Amendola et al who attributed the absence of spontaneous 
colonic inflammation in NOD2-deficient mice to permeability 
changes: the latter may increase the exposure of dendritic 
cells to factors, such as TLR ligands, that influence T-reg cell 
development and subsequent changes in the microbiota.115
Homozygous/compound heterozygous carriage of the 
CD-associated NOD2 variants has been reported to be signifi-
cantly associated with ileal disease involvement, stricturing/ 
stenosing disease behavior and 2–3 years earlier age of dis-
ease onset compared to NOD2 WT CD patients.116,117 Ileal 
CD patients with NOD2 L1007fs mutation showed a reduced 
release of α-defensin from Paneth cells.118,119
Interestingly, the reduction of α-defensin release seems 
to be a secondary effect of the NOD2 knockdown, causing 
excessive inflammation and loss of Paneth cell. However, the 
question remains controversial.120
Notably, CD-associated NOD2 variants are defective in 
ATG16L1 recruitment and exhibit an altered autophagy in a 
cell type-specific manner.91 Furthermore, in patients with ileal 
CD, mutations in autophagy genes other than in NOD2 lead 
to an impaired secretion of Paneth cell-derived α-defensins 
with a deficiency in clearance of internalized bacteria.119–122 
Therefore, the combination of defective innate immune 
responses by NOD2 and ineffective bacterial clearance by 
autophagy could together be responsible for CD development 
and progression.
NOD2 and extraintestinal diseases
A consistent issue in human genetics is that genes implicated 
in one disorder could potentially increase susceptibility in 
other related disorders. It has been shown that three major 
missense mutations in the NBD domain of NOD2, R334Q, 
R334W and L469F are involved in an extremely rare, mono-
genic dominant disorder characterized by granulomatous 
inflammatory arthritis, uveitis and dermatitis, known as 
BS.45,123,124 The latter is related to gain-of-function mutations 
as opposed to CD mutations which appear to be recessive 
and are characterized with respect to NF-κB activation by a 
loss of function.44 More rarely, the NOD2 R314Q polymor-
phism, coding for a truncated form of the protein, has also 
been found to be associated with BS.8
NOD2 mutations, leading to increased activity of NF-κB, 
have been associated to EOS, a multisystemic granuloma-
tous disease characterized by arthritis, uveitis and cutaneous 
involvement.125 NOD2 mutations and similar clinical and his-
tologic characteristics suggest a link between EOS and BS.9,47
Increased NOD2 expression has been found in patients 
with rheumatoid arthritis, a chronic inflammatory disorder 
that affects the joints, causing structural deformities.126 Upon 
stimulation with MDP, peripheral blood mononuclear cells 
isolated from rheumatoid arthritis patients produced high 
amounts of TNFα, IL-8 and IL-1β, while NOD2 downregu-
lation significantly decreased proinflammatory cytokines, 
NF-κB, TRAF6 and IKK levels.127
Clinical and experimental studies have recently shown a 
role of NOD2 in cardiovascular diseases inducing vascular 
inflammation and severity of atherosclerosis, the most com-
mon pathologic process of coronary artery and cerebrovas-
cular disease.128 NOD2 has been localized in inflamed areas 
of atherosclerotic lesions and is overexpressed in endothelial 
cells delimiting the lumen of diseased vessels.129 Moreover, 
NOD2-mediated IL-6, IL-8 and IL-1β production induces 
vascular inflammation and promotes expansion of the lipid-
rich necrotic areas.130
NOD2 mRNA has also been found to be highly expressed 
in bronchoalveolar lavage and in peripheral blood mono-
nuclear cells from patients with Behcet’s disease, a rare 
disorder with unknown etiology, characterized by a systemic 
vasculitis and pulmonary manifestations.131,132 A recent study 
has shown that NOD2 aggravates myocardial ischemia/
reperfusion injury by inducing cardiomyocyte apoptosis and 
inflammation through JNK, p38MAPK and NF-κB signal-
ing in mice and has suggested NOD2 as a potential target 
for the treatment of the disease.133 Furthermore, NOD2 has 
been reported to be involved in IL-6, IL-8 and monocyte 
chemoattractant protein-1 production induced by the invasion 
of human aortic endothelial cells by Streptococcus mutans, 
the primary etiologic agent of dental caries, associated with 
the development of cardiovascular disease.134
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NOD2 variants have been associated with the systemic 
autoinflammatory disease (NOD2-associated autoinflamma-
tory disease), a genetically complex multisystem disorder 
characterized by periodic fever, dermatitis, arthritis and gas-
trointestinal and sicca-like symptoms, but with a phenotypic 
and genotypic profile distinct from CD.135
NOD2 polymorphisms have been also related to atopic 
dermatitis, a chronically relapsing inflammatory skin disease 
associated with basophil infiltration and an exacerbation of 
inflammation by Sta. aureus.136–138
Recent literature describes a central role of NOD2 
in susceptibility to obesity and metabolic dysfunction.139 
NOD2-deficient mice show increased bacterial adherence to 
the intestinal mucosa and bacterial infiltration in metabolic 
tissues, such as hepatic and adipose tissue, exacerbating 
inflammation and insulin resistance.140 Moreover, NOD2−/− 
BALB/c mice have shown susceptibility to obesity, hyper-
lipidemia, hyperglycemia, glucose intolerance, increased 
adiposity and hepatic steatosis, as compared to WT mice.141
Finally, NOD2-increased expression has been observed 
in patients with active Vogt–Koyanagi–Harada disease, a rare 
granulomatous inflammatory disease that affects pigmented 
structures, promoting proinflammatory cytokine production 
and Th1 and Th17 cells stimulation.142
NOD2 and cancer
NOD2 has been associated to cancer development. Data 
from animal models indicate that NOD2 deficiency leads 
to dysbiosis resulting in increased risk of colitis and colitis 
associated colorectal cancer.143 A recent study in NOD2- or 
RIP2-deficient mice shows an increased epithelial dysplasia 
following dextran sulfate sodium-induced colitis, suggesting 
a NOD2-protective role in cancer development via regulation 
of gut bacterial equilibrium.55
Emerging evidence in human studies implies that several 
NOD2 polymorphisms may influence individual susceptibil-
ity to cancer.143,144 However, the results are still inconclusive 
due to confounding genetic, bacterial and environmental 
factors that may alter variant allele penetrance or the differ-
ences in sample size, geographic variation and genotyping 
methods. In general, NOD2 gene polymorphisms are associ-
ated with altered risk of gastric, colorectal, breast, ovarian, 
prostate, testicular, lung, laryngeal, liver, gallbladder, biliary 
tract, pancreatic, small bowel, kidney, urinary bladder cancer, 
skin cancer, non-thyroid endocrine tumors, lymphoma and 
leukemia.145 In particular, the three most common NOD2 
polymorphisms, rs2066844 C/T (R702W), rs2066845 C/G 
(G908R) and rs2066847 (3020insC), have been associated 
with increased risk of gastrointestinal cancer.146 Furthermore, 
NOD2 has also been involved in the development of gastric 
cancer induced by Helicobacter pylori.144
Conclusion
The involvement of NOD2 in the pathogenesis of several 
genetic diseases indicates that this protein is a key regulator 
of immune and inflammatory responses. Extensive studies 
have evidenced a fundamental role of NOD2 in maintaining 
the equilibrium between bacteria, epithelia and innate immune 
response of the host. This protective function is lost in case of 
NOD2 mutations, resulting in exacerbated inflammation and 
the onset of various diseases. On the other hand, inappropriate 
activation of WT NOD2 is reported in many chronic inflam-
matory diseases, resulting in continuous production of proin-
flammatory mediators, but the exact mechanism underlying 
this NOD2 dysregulation is not yet well established. Recent 
literature has shifted the interest from genetic to epigenetic 
control and to interactions with other innate immune pathways 
such as autophagy and ER stress. Many questions remain 
unanswered, including the relation between NOD2 mutations 
and microbiota and the understanding of the processes by 
which mutations in the NOD2 could be associated with the 
susceptibility to inflammation and development of diseases. 
When the exact mechanism of regulation and functions of 
NOD2 will be unraveled, it could lead to the development of 
more effective therapies for inflammatory disorders.
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